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Abstract
High tumor recurrence is frequently observed in patients with urinary bladder cancers (UBCs), with the need
for biomarkers of prognosis and drug response. Chemoresistance and subsequent recurrence of cancers are
driven by a subpopulation of tumor initiating cells, namely cancer stem-like cells (CSCs). However, the
underlying molecular mechanism in chemotherapy-induced CSCs enrichment remains largely unclear. In this
study, we found that during gemcitabine treatment lncRNA-Low Expression in Tumor (lncRNA-LET) was
downregulated in chemoresistant UBC, accompanied with the enrichment of CSC population. Knockdown of
lncRNA-LET increased UBC cell stemness, whereas forced expression of lncRNA-LET delayed
gemcitabine-induced tumor recurrence. Furthermore, lncRNA-LET was directly repressed by gemcitabine
treatment-induced overactivation of TGFβ/SMAD signaling through SMAD binding element (SBE) in the
lncRNA-LET promoter. Consequently, reduced lncRNA-LET increased the NF90 protein stability, which in
turn repressed biogenesis of miR-145 and subsequently resulted in accumulation of CSCs evidenced by the
elevated levels of stemness markers HMGA2 and KLF4. Treatment of gemcitabine resistant xenografts with
LY2157299, a clinically relevant specific inhibitor of TGFβRI, sensitized them to gemcitabine and significantly
reduced tumorigenecity in vivo. Notably, overexpression of TGFβ1, combined with decreased levels of
lncRNA-LET and miR-145 predicted poor prognosis in UBC patients. Collectively, we proved that the
dysregulated lncRNA-LET/NF90/miR-145 axis by gemcitabine-induced TGFβ1 promotes UBC
chemoresistance through enhancing cancer cell stemness. The combined changes in
TGFβ1/lncRNA-LET/miR-145 provide novel molecular prognostic markers in UBC outcome. Therefore,
targeting this axis could be a promising therapeutic approach in treating UBC patients.
Key words: tumor recurrence, cancer stem-like cells, lncRNA-LET, miRNA biogenesis, bladder cancer.

Introduction
Urinary bladder cancer (UBC) is highly
recurrent. Although cytotoxic chemotherapeutic
reagents such as gemcitabine (GEM) work well for
most patients initially, a majority of patients treated
with GEM progressively become unresponsive after
multiple rounds of treatments, and ultimately lead to
tumor relapse. Chemotherapies are usually

administered in cycles for fractionated killing of
unsynchronized proliferating cancer cells; meanwhile
they allow recovery of cells in normal tissues.
However, this regimen also provides an opportunity
for residual cancer cells to survive (1). Results from
recent studies suggest that a small subpopulation of
cells with cancer stem-like properties has a survival
http://www.thno.org
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advantage in response to chemotherapy and may be
responsible for tumor recurrence (2-5). This
subpopulation is also known as cancer stem-like cells
(CSCs) or tumor-initiating cells (TICs) because they
retain the capacity of self-renewal and repopulation of
the whole tumor bulk (6-8). However, the molecular
mechanism in GEM-induced CSCs enrichment in
UBC remains unclear, which hampers the application
of treatments specifically targeting CSCs.
Treatment-induced cancer cell death may also be
accompanied with inflammation, which has been
implicated in the development of chemoresistance
(9-12). Some pro-inflammatory cytokines derived
from either dying cancer cells or tumor
microenvironment are involved in cancer relapse.
TGFβ1 is one of the most potent cytokines capable of
inducing epithelial-to-mesenchymal transition (EMT),
which is highly associated with the characteristics of
CSCs (13).
Long noncoding RNAs (lncRNAs) are those
RNA molecules with more than 200 nucleotides.
Although lncRNAs do not code for any proteins, they
have been implicated in different processes of cancer
development including initiation, promotion and
metastasis (14). Results from more recently reported
studies also suggest that lncRNAs play important
roles in the maintenance of cancer cell stemness and
chemoresistance (15). Some lncRNAs appear to have
the potential to be developed into prognosis
biomarkers for chemotherapy (16). LncRNAs regulate
gene expression at multiple levels, including
transcriptional regulation through interacting with
chromatin-modifying factors and post-transcriptional
regulation through targeting mRNAs, miRNAs and
proteins. How lncRNAs-mediated pro-inflammatory
cytokines function in CSC and the downstream
networks involved in chemoresistance are elusive. In
this study, we found that CSCs were highly enriched
in UBC in response to GEM treatment.
Mechanistically,
GEM
treatment-mediated
upregulation of TGFβ1 directly involved in the
dysregulation of lncRNA-LET/NF90/miR-145 axis.
Therefore, targeting this axis could be a potential
therapeutic strategy with less recurrence.

Materials and Methods
Cell lines and human cancer tissues
Human UBC cell lines, T24, 5637, J82, SW780,
BIU87, ScaBER and UMUC3 were obtained from Cell
Bank of Type Culture Collection, Chinese Academy of
Science (Shanghai, China). Cells were maintained in
RPMI1640 supplemented with 10% FBS, 100 units/ml
penicillin and 100 μg/ml streptomycin at 37oC. J82
cells were treated with 50 μg/ml cycloheximide
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(CHX; Sigma) or 20 μM MG-132 (Sigma) for 3, 6 or 12
h before lysed for protein analysis. For TGFβ1
experiment, UBC cells were treated with 2 nM TGFβ1
(Proteintech, 100-21, Rocky Hill, NJ) for 48 h, and if
needed, 10 nM SB431542 (Selleck Chemical, S1067,
Boston, MA) was added 1 h prior to TGFβ1 treatment.
UBC tissues (n = 60) and adjacent non-tumor
tissues (n = 48) were collected from Nanjing Drum
Tower Hospital affiliated to Nanjing University
(Jiangsu, China) from January 2012 to October 2013.
Fresh tissue samples were collected and processed
within 10 min. Each sample was snap-frozen in liquid
nitrogen and then stored at -80°C. The paired adjacent
normal tissues were isolated from at least 3 cm away
from tumor boarder and with no microscopic tumor
cells. All cases were in accord with the following
criteria: diagnosed by postoperative histopathology;
complete follow-up data available; no metastasis
before surgery; no other malignant disease; and no
preoperative anticancer therapy. We defined tumor
recurrence as any radiological or pathological tumor
found after surgery. Tumor staging was defined
according
to
the
7th
Edition
of
Tumor-Node-Metastasis (TNM). The data do not
contain any information that could identify the
patients. Informed consent was obtained in
accordance with the Declaration of Helsinki and the
protocols were approved by the Nanjing Drum Tower
Hospital Ethics Committee of Medicine for tissue
sample collection (201203601).

RNA isolation, quantitative reverse
transcription-PCR (qRT-PCR), microarray and
RNA immunoprecipitation (RIP) assays
Total RNAs were extracted using TRIzol
(Invitrogen, 15596018), following the manufacturer’s
instructions. Small RNAs were extracted from tissue
or cells using miRNeasy Mini isolation kit (QIAGEN).
Reverse transcription of mRNA and miRNA was
conducted using random primers and primers of
stem-loop in TaKaRa system (Dalian, China),
respectively. The levels of pri-miRNAs were
quantified using the TaqMan Pri-miRNA assay kit
(Assay ID Hs03303166_pri for pri-miR-143, Assay ID
Hs03303169_pri
for
pri-miR-145;
Applied
Biosystems). Real-time PCR was performed using
TaqMan Universal Master Mix II kit (Applied
Biosystem). The levels of target genes were calculated
based on the cycle threshold (Ct) values compared to
a reference gene using formula 2-∆∆Ct. β-actin (ACTB)
mRNA and U6 (RNU6B) snRNA were used as
references for mRNA and mature miRNA,
respectively. Sequences of the primer were listed in
Table S1. For lncRNA profiling, Human lncRNA
Discover
PCR
array
(Bio-Serve
Company,
http://www.thno.org
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BS-lncRNA002, Shanghai, China) was used.
Affymetrix miRNA 4.0 microarray was used and
performed by GMINIX Company (China).
For RIP assays, cells were irradiated with 254 nm
UV light (400 mJ/cm2), and homogenized in lysis
buffer [150 mM KCl, 50 mM HEPES (pH 7.4), 2 mM
EDTA, 0.5 mM DTT, 0.5% NP-40 containing 10 U/ml
RNase inhibitor (TaKaRa) and a protease inhibitor
cocktail (Roche)]. Cell extracts were incubated with
anti-NF90 or IgG-coupled protein A beads for 4–6 h at
4°C in NT2 buffer (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 1 mM MgCl2, 0.05% NP-40). After stringently
washing the beads with washing buffer [50 mM
HEPES (pH 7.4), 300 mM KCl, 0.5 mM DTT, 0.05%
NP-40, protease inhibitor cocktail, and RNase
inhibitor], total RNAs were extracted with TRIzol and
subjected to RT-PCR assays.

Immunoblotting
Cells or tissues were lysed in RIPA buffer
containing phosphatase inhibitor cocktail I (Sigma)
and protease inhibitor cocktail mini-tablet (Roche
Diagnostics, Indianapolis, IN). Proteins in the lysates
were separated on SDS-PAGE and transferred onto
polyvinylidenedifluoride membrane. After blocking
with 5% non-fat milk in PBST, primary antibodies for
ALDH1A1 (1:500, Proteintech Group, 22109-1-AP,
Chicago, IL), CD44 (1:500, Cell Signaling Technology,
#3570, Beverly, MA), KLF4 (1:500, Proteintech,
11880-1-AP),
HMGA2
(1:500,
Proteintech,
20795-1-AP), NF90 (1:1,000, ImmunoWay, YT5036,
Newark, DE), FLAG-tag (1:2,000, Cell Signaling
Technology, #2368), SMAD4 (1:500, Proteintech,
10231-1-AP), p-SMAD2 (1:250, Phospho-Ser467,
Signalway Antibody, 11322, College Park, MA),
SMAD2 (1:500, AP0444) and β-actin (1:2,000,
Bioworld) were used. The membranes were washed
with PBST three times and incubated with
horseradish peroxidase (HRP)-conjugated secondary
antibody. The bands were visualized using enhanced
chemiluminescence reagents (Millipore, WBKLS0100).
Western blots were semi-quantified by Image J
software (NIH).

Sphere formation assay
T24, 5637 cells and xenografts were trypsinized
by TrypLE (Life Technologies) and washed in PBS.
About 1.0×104 cells per well were seeded in the 6-well
ultra-low attachment plates (Corning, Steuben
County, NY) in DMEM/F12 culture medium
supplemented with 10 ng/ml human recombinant
bFGF and 10 ng/ml EGF (PeproTech, Rocky Hill, NJ).
After culturing for 9-12 days with or without TGFβ1
and/or SB-431542, spheres were photographed and
spheres with the diameter greater than 50 µm were
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counted.

Flow cytometry
Cells with high ALDH enzyme activity was
identified by ALDEFLUOER kit (Stem Cell
Technologies, Vancouver, Canada). 5 µl of activated
ALDEFLUOER reagent was added to 1 ml single cell
suspension and incubated at 37°C for 40 min. An
ALDH-specific inhibitor, Diethylaminobenzaldehyde
(DEAB), was added prior to staining as a negative
control.

Luciferase assay
Luciferase assays were performed using a
luciferase assay kit (Promega). For TGFβ/SMAD
pathway, T24 cells were transfected with plasmids
containing wild-type or ∆SBE pGL3-LET-promoter
and treated with vehicle control or TGFβ1,
respectively. Cells were harvested and lyzed for
luciferase assay 48 h post transfection. Renilla
luciferase was used for normalization.

In vivo tumor xenograft study
Animal studies were approved and carried out
in accordance with Institutional Animal Care and Use
Committee of Model Animal Research Center,
Nanjing University. 5×106 of T24, 5637 and
lncRNA-LET stable over-expression cells (vector
control and pLET) in 0.1 ml 50% Matrigel were
injected subcutaneously into the right flank of
4~6-week-old male nude mice. 10 days post
inoculation, tumor-bearing mice were randomized to
saline or GEM groups. GEM (50 mg/kg body weight)
was given on day 1, 4, 8 and 11 via intraperitoneal
injection. Tumor diameters were measured with
calipers every 3 days and tumor volumes were
calculated by the formula: tumor volume = π× length
× width2/6. The tumors were harvested 24 h after the
last treatment and snap frozen or fixed in 10%
formalin, followed by embedding in paraffin.
Xenografts were rinsed in PBS and mechanically
minced with sterile blades in RPMI1640/5% FBS with
antibiotics/antimycotics and digested with 0.5%
trypsin for 5 to 10 minutes at 37°C. The dissociated
cells were strained through strainer (BD) and cultured
as primary cells. Cell viability was verified by trypan
blue exclusion before FACS analysis, sphere assays or
immunoblotting.
To investigate combined TGFβ signaling
inhibition and gemcitabine treatment, we treated mice
with type I TGFβ receptor kinase inhibitor LY2157299
(100 mg/kg body weight, Selleck) twice a day via
orogastric gavage and GEM (50 mg/kg body weight)
on day 1, 4, 8 and 11 via intraperitoneal injection.

http://www.thno.org
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Limiting dilution analysis of tumor
subpopulations
shCTL and shLET cells were serially diluted to
the designated cell number, followed by the
subcutaneous injection into nude mice. The number of
tumors formed from each injection was scored. The
frequency of CSCs had been calculated using ELDA
software
(http://bioinf.wehi.edu.au/software/elda/index.ht
ml) provided by the Walter and Eliza Hall Institute.

Immunohistochemistry (IHC)
5 µm-thick paraffin-embedded sections were
used for IHC staining. Primary antibodies against
CK5 (Covance, PRB-160P) and CK14 (Covance,
PRB-155P) were incubated overnight at 4°C. After
washing, biotinylated secondary antibody (Maxin,
KIT-9707) was applied, followed by the procedures
described previously (17).

Statistics
Data are presented as mean±standard deviation
(SD) from three independent experiments unless
specially stated. Mann Whitney test, Unpaired t test or
Wilcoxon signed rank test was used to compare the
differences of the level between cancer tissues and
corresponding normal tissues. Other differences
between groups were analyzed using Student’s t test
or One-way ANOVA followed by Newman-Keuls
multiple comparison test. Pearson correlation test was
used for analyzing the correlation between two
continuous factors. The log-rank (Mantel-Cox) t-test
was used for survival analysis. P value less than 0.05
was considered statistically significant.

Results
GEM treatment enriches UBC stem-like cells
To mimic the process of tumor recurrence in
GEM-treated patients, we first inoculated human
UBC cell lines T24 or 5637 into nude mice
subcutaneously and then 50 mg/kg of GEM were
administered to the mice on days 1, 4, 8 and 11,
followed by a two-week recovery period. The second
round treatment started on day 29 for mice with T24
and 5637 xenografts, and the third round treatment
started on day 57 for mice carrying 5637 xenografts.
As shown in Fig. 1A and Fig. S1A, overall the tumors
derived from either of these cell lines grow much
slower in the GEM-treated mice than those in the
vehicle group. During the first two weeks, GEM
almost completely inhibited the growth of tumors
derived from either of these cell lines. During the
two-week recovery period, tumors grew much faster
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in control group, although the tumor growth rate was
still lower in the GEM group. However, GEM failed to
inhibit the growth of T24 and 5673 xenografts in the
second and the third round of treatment, respectively.
To explore the possibility that some of the tumor
cells become resistance to GEM treatment due to a
subpopulation of CSCs, we sacrificed the mice and
collected tumor samples at the end of the 2nd round
(T24 xenografts) and the 3rd round (5637 xenografts)
of treatments for further analyses. Firstly, we isolated
cancer cells from xenografts and performed sphere
assays. As shown in Fig. 1B and Fig. S1B, compared to
that in the vehicle group, cells in GEM-treated group
increased the number of spheres derived from T24
and 5637 xenografts by 2.3 and 2.2 folds, respectively.
Consistently, IHC analyses showed that two UBC
stemness markers CK5 and CK14 (18) were highly
expressed in the GEM-treated xenografts (Fig. 1C and
Fig. S1C). Furthermore, Western blotting showed that
another four CSC markers (ALDH1A1, CD44, KLF4
and HMGA2) (19-24) elevated dramatically in the
GEM-treated samples (Fig. 1D and Fig. S1D). Finally,
we treated T24 and 5637 cells in vitro with GEM at IC50
values for T24 (3.8 μM) and 5637 (6.4 μM) cells,
respectively, followed by the removal of GEM for
cancer cell recovery (Fig. S2A and S2B). Compared
with the vehicle, GEM treatment significantly
increased the ALDHhigh population from 7.9% to
12.6% for T24 cells, and from 9.7% to 19.0% for 5637
cells (Fig. S2C). GEM-treatment also increased the
CD44+ subpopulation, another CSC marker for UBC
cells (Fig. S2D) and the levels of different CSC
markers (Fig. S2E). Taken together, these data suggest
that GEM treatment can enrich the CSC
subpopulation in UBC.

Downregulation of lncRNA-LET negatively
correlates with cancer stemness
To determine if lncRNAs play any roles in CSC
enrichment resulted from GEM treatment, we carried
out cancer-related lncRNA PCR array. GEM treatment
upregulated 14 and 6 lncRNAs in T24 and 5637
xenografts, respectively; meanwhile 5 and 14
lncRNAs were downregulated by GEM treatment,
respectively. Among them, lncRNA-LET was the only
lncRNA that was downregulated more than 2 folds in
GEM-treated xenografts derived from both T24 and
5637 cells (Table S2). The array results were further
validated in these cell lines treated with or without
GEM (Fig. 1E). LncRNA-LET was first found to be
downregulated in hepatocellular carcinomas (25).
However, its exact function in chemoresistance is
unclear. Therefore, we decided to focus on this
lncRNA for further study.

http://www.thno.org
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Figure 1. Cancer stemness markers in cells treated with chemotherapeutic agents in vivo, and downregulation of lncRNA-LET enhances
CSC-like properties. (A) In vivo GEM chemotherapy simulates clinical regimen with multiple GEM treatment cycles (dashed boxes) and gap periods. Tumor sizes
of T24 xenografts were measured for GEM treatment and vehicle control group (n = 6 per group). (B) Sphere formation assay of primary cells derived from T24
xenografts of control group (Veh) and GEM (n=3 per group). (C) Representative H&E and IHC data showing the expression levels of CSC markers (CK5 and CK14)
in T24 xenografts of control and GEM groups (n = 6 per group). (D) Western blotting of CSC markers (ALDH1A1, CD44, KLF4, and HMGA2) in T24 xenografts of
control and GEM groups. (E) The levels of lncRNA-LET in T24 and 5637 cells treated with GEM or vehicle. (F) Knockdown efficiency of lncRNA-LET in T24 cells and
forced expression of lncRNA-LET in J82 cells. (G-H) ALDHhigh population (G) and CSC markers (H) were determined by flow cytometer and Western blotting in T24
with knockdown and J82 cells with overexpression of lncRNA-LET (n=3 per group). (I) Knockdown efficiency of lncRNA-LET in T24 cells infected with shRNA
targeting lncRNA-LET virus (shLET), compared to control (shCTL). (J) Tumor volume of shCTL and shLET T24 cells with limiting dilution. Each dot represents an
individual mouse (n=6 per group). Data are shown as mean ± SD and represent three independent experiments with similar results. * P < 0.05; ** P < 0.01, *** P <
0.001 (Student’s unpaired two-tailed t-test). (K) CSC frequency was calculated using extreme limiting dilution analysis (ELDA). There was a significant difference in
CSC frequency between two groups, with a P value of 0.025.

Next, we examined the expression of
lncRNA-LET in several UBC cell lines. 5637 cells
express the highest levels of lncRNA-LET, followed
by T24 cells and the least in J82 cells (Fig. S1E). To
determine the effect of lncRNA-LET on cancer
stemness in UBC cells, lncRNA-LET was knocked
down by two siRNAs, siLET-#1 and siLET-#2, in T24
and 5637 cells and overexpressed in J82 cells (Fig. 1F
and Fig. S1F). The ALDHhigh populations and the
levels of cancer stemness markers were assessed. As
shown in Fig. 1G and Fig. S1G, depletion of
lncRNA-LET increase ALDHhigh populations in T24
and 5637 cells. On the other hand, overexpression of
lncRNA-LET in J82 cells reduced the ALDHhigh
population by about 50% (Fig. 1G). Western blotting
further confirmed the inhibitory effects of

lncRNA-LET on UBC stemness, evidenced by the
levels of CSC markers (Fig. 1H and Fig. S1H).
To further confirm the effects of lncRNA-LET on
UBC stemness in vivo, we then established
lncRNA-LET stable knockdown cells (shLET; Fig. 1I),
and conducted the limiting dilution assay to
rigorously test the cells’ tumor-initiating capacity. We
found that depletion of lncRNA-LET significantly
increased both cancer incidence and tumor volumes
(Fig. 1J and K). To test whether forced expression of
lncRNA-LET can reverse tumor recurrence in vivo, we
stably overexpressed lncRNA-LET in T24 cells (Fig.
2A), and as expected that overexpression of
lncRNA-LET reduced the levels of the stemness
markers (Fig. 2B). Then we inoculated the cells with
lncRNA-LET overexpression into nude mice,
http://www.thno.org
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followed by GEM treatment. As shown in Fig. 2C-D,
forced expression of lncRNA-LET increased tumor
latency with GEM treatment. IHC data showed that
CK5 and CK14 were highly induced by GEM
treatment in control but not the lncRNA-LET group
(Fig. 2E). These data collectively demonstrate that
lncRNA-LET is essential and sufficient for
maintenance of UBC stemness, whereas forced
overexpression of lncRNA-LET could partially
reverse chemoresistance in UBC.

LncRNA-LET is suppressed by TGFβ1
signaling in chemoresistant cells
Given the facts that inflammation was proposed
to be involved in the development of cancer stemness
and GEM treatment might induce inflammation (9),
we decided to determine if downregualtion of
lncRNA-LET by GEM treatment is due to the
activation of the inflammatory pathway. We
examined a few well-established pro-inflammatory
cytokines in T24 xenografts treated with or without
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GEM. Among these factors, TGFβ1 is significantly
increased when the cells were treated with GEM
accompanied with a couple of factors directly
involved in the TGFβ signaling pathway (Fig. S3A).
This observation was also substantiated by Western
blotting,
showing
phosphorylated
SMAD2
(p-SMAD2) in T24 xenografts by GEM treatment (Fig.
3A). In addition, the levels of lncRNA-LET were
downregulated by TGFβ1 in both cell lines, and this
effect was likely through TGFβRI because the
TGFβ1-downregulated lncRNA-LET was successfully
rescued by treating cells with either TGFβRI inhibitor
SB-431542 (Fig. 3B and Fig. S3B) or SMAD4 siRNAs
(Fig. 3C and Fig. S3C). Furthermore, TGFβ1 enhanced
cancer stemness, evidenced by its effects on the
number of spheres (Fig. S3D-E) and the ALDHHigh
subpopulation (Fig. S3F). Overall, both TGFβRI and
SMAD4 are important for TGFβ1-induced cancer
stemness and the level of lncRNA-LET.

Figure 2. The role of lncRNA-LET in GEM-induced cancer stemness. (A) qRT-PCR showed stable overexpression of lncRNA-LET in T24 cells (pLET). (B)
CSC markers were determined by Western blotting in T24 cells overexpressed lncRNA-LET and control vector. (C-E) Tumor size change (C), the levels of
lncRNA-LET (D) and representative IHC (E) of xenografts from control (Vec) and overexpression (pLET) cells after GEM or vehicle treatment (Vec+Veh group n=5,
other group n=6). Dashed boxes indicate the time frame of each GEM chemotherapy cycle. Data are shown as mean ± SD and represent at least two independent
experiments with similar results. * P < 0.05, ** P < 0.01, *** P < 0.001 (One-way ANOVA followed by Newman-Keuls multiple comparison test).

http://www.thno.org
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Figure 3. TGFβ1 represses lncRNA-LET expression in UBC cells. (A) Western blotting showing the levels of p-SMAD2 and total SMAD2 in xenografts
treated with or without GEM. (B-C) mRNA levels of lncRNA-LET were measured by qRT-PCR in T24 and 5637 cells treated with or without TGFβ1 or TGFβR1
inhibitor, SB-431542, as well as transfected with control (siNC) or 2 different RNAi of SMAD4 (siSMAD4#1, siSMAD4#2), followed by vehicle or TGFβ1 treatment.
(D) Conserved SMAD4 binding element (SBE) in the promoter of human and Rhesus Monkey lncRNA-LET. (E) Relative luciferase activity in T24 cells transfected
with plasmids of wild type (pGL3-LET-WT) and SBE deleted (pGL3-LET-ΔSBE) lncRNA-LET promoter, respectively, followed by treatment with vehicle or TGFβ1.
(F-G) Sphere numbers (F) and expression of CSC markers (G) in T24 and 5637 cells treated with TGFβ1 alone or TGFβ1 and forced expression of lncRNA-LET.
Data are shown as mean ± SD and represent at least two independent experiments with similar results. * P < 0.05, ** P < 0.01, *** P < 0.001 (Student’s unpaired
two-tailed t-test).

Additionally, results from bioinformatic analysis
identified a conserved SMAD binding element (SBE)
in the promoter region of lncRNA-LET (Fig. 3D). The
wild-type or ∆SBE-mutant lncRNA-LET promoter
sequence was cloned into pGL3-basic plasmid and
luciferase activities were measured in cells treated
with or without TGFβ1. Fig. 3E shows that TGFβ1
repressed the promoter activity of wild-type but not
the mutant reporter, suggesting that lncRNA-LET is a
downstream target of the canonical TGFβ signaling
pathway. To further validate the essentiality of
lncRNA-LET downregulation in TGFβ-induced
cancer stemness, we forcedly expressed lncRNA-LET

in T24 and 5637 cells. Overexpression of lncRNA-LET
reversed TGFβ1-induced cancer stemness, with
increase of sphere number (Fig. 3F) and the
expression levels of CSC markers (Fig. 3G). These data
collectively demonstrate that lncRNA-LET negatively
regulates TGFβ1-induced cancer stemness.

NF90 is essential in GEM-induced
lncRNA-LET-mediated UBC stemness
Since lncRNA-LET has been implicated in the
regulation of NF90 protein stability in hepatocellular
carcinoma (25), we decided to examine if NF90 is
regulated by lncRNA-LET in UBC. As shown in Fig.
http://www.thno.org
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4A and Fig. S4A, knockdown of lncRNA-LET
increased NF90 protein level in both T24 and 5637
cells; whereas forced expression of lncRNA-LET in J82
cells reduced the level of NF90. To test whether
lncRNA-mediated NF90 downregulation is through
enhancing protein degradation, we treated cells with
cycloheximide (CHX) and evaluated NF90 levels at
different time points. The half-life of NF90 was about
12 h in the control, which was reduced to about 3 h in
the cells with lncRNA-LET overexpression (Fig. 4B),
suggesting
that
lncRNA-LET-mediated
NF90
downregulation was through enhancing protein
degradation. In addition, NF90 protein degradation
by lncRNA-LET was significantly inhibited in the
presence of MG-132, an inhibitor against 26S
proteasome, indicating the involvement of the 26S
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proteasome system (Fig. S4B). Next, we tested
whether NF90 is required for lncRNA-LET-mediated
cancer cell stemness. Consistent with the
aforementioned experiments, lncRNA-LET depletion
increased ALDHhigh populations in both T24 and 5637
cells. However, simultaneous knockdown of NF90
and lncRNA-LET significantly reduced ALDHhigh
population, compared to knockdown of lncRNA-LET
alone (Fig. 4C and Fig. S4C). These findings were
further verified by Western blotting (Fig. 4D and Fig.
S4D). Given the fact that GEM could increase NF90 at
protein level in GEM-resistant cells (Fig. 4E and Fig.
S4E) and knockdown of NF90 reduces GEM-induced
ALDHhigh population and CSC markers (Fig. 4F-G and
Fig. S4F), we conclude that NF90 is essential for
GEM-induced lncRNA-LET-mediated UBC stemness.

Figure 4. The stabilized NF90 by the reduced lncRNA-LET is required for cancer cell stemness. (A) Western blotting showing NF90 protein level in
T24 with depletion of lncRNA-LET and J82 cells with overexpression of lncRNA-LET. (B) Protein level of NF90 in J82 cells over-expressed lncRNA-LET, followed by
50 μg/ml cycloheximide (CHX) treatment for the indicated time points. (C-D) ALDHhigh population (C) and expression of CSC markers (D) were determined by
flow cytometer and Western blotting in control (siNC), lncRNA-LET knockdown (siLET#2), and simultaneous knockdown lncRNA-LET and NF90 (siLET#2 +
siNF90#1 or siLET#2 + siNF90 #2) of T24 cells (n=3 per group). (E) Protein level of NF90 was determined by Western blotting in untreated and GEM resistant T24
cells. (F) The ALDHhigh population was determined by flow cytometer in control (siNC) and NF90 knockdown (siNF90 #1 and #2) T24 cells treated with or without
GEM. (G) Western blotting showing the levels of CSC markers in control (siNC) and NF90 knockdown (siNF90 #1 and #2) T24 cells, followed by the treatment with
or without GEM. Data are shown as mean ± SD and represent at least two independent experiments with similar results. * P < 0.05, ** P < 0.01, *** P < 0.001
(Student’s unpaired two-tailed t-test).
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NF90 negatively regulates miR-145 biogenesis
As a RNA binding protein, NF90 plays an
important role in mRNA stability and miRNA
biogenesis (26). We first tested the effect of NF90 on its
two known targets VEGF and HIF1α in 5637 cells and
found that lncRNA-LET depletion upregulated NF90
and VEGF at protein levels, but not HIF1α, probably
due to different cell type (Fig. S5A). Since the role of
VEGF in UBC cell stemness is not well-established
and it has been reported that NF90 could be involved
in miRNA biogenesis, we conducted microarray assay
to identify miRNAs potentially regulated by NF90
(GSE 82024) and found that NF90 knockdown
resulted in upregulation of 25 miRNAs (≧ 2 folds)
and downregulation of 9 miRNAs (≦ 0.5 fold) (Fig.
5A). Among them, miR-145 was the most highly
upregulated miRNAs with 22.5-fold induction. Of
note, although miR-143 and miR-145 locate in the
same region on the chromosome, the levels of miR-143
was not affected significantly under the same
condition.
Next, we validated the effect of NF90 on miR-145
in T24 and 5673 cells with miR-143 as a control. Fig. 5B
showed that when NF90 was knocked down by
siNF90 #1, miR-145 was upregulated by 22.6 and 14.7
folds in T24 and 5637 cells, respectively. Another
siRNA targeting different region of NF90 (siNF90 #2)
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was also used and confirmed the induction of
miR-145 when NF90 was depleted (Fig. S5B, left
panel). However, NF90 knockdown had no effects on
miR-143 (Fig. S5B, middle and right panels).
Consistent with the fact that NF90 is a lncRNA-LET
target and NF90 knockdown upregulated miR-145,
inhibition of lncRNA-LET resulted in downregulation
of miR-145 in both cell lines (Fig. 5C). Again, knocking
down lncRNA-LET had undetectable effect on
miR-143 (Fig. 5D). Consistently, lncRNA-LET
overexpression was capable of upregulating miR-145
without affecting miR-143 (Fig. S5C). To test whether
NF90 regulates miR-145 through direct interaction,
we conducted RIP assay. As shown in Fig. 5E, NF90
interacted specifically with pri-miR-145, but not
pri-miR-143. To demonstrate that NF90 interacts with
pri-miR-145 through the conserved NF90 binding
sequence (27), we synthesized both wild-type and
mutant miR-145 with the change of 5’-CTGTT-3’ to
5’-CTGCC-3’ and estimated the effect of NF90 on
these pri-miRNAs (Fig. 5F). Fig. 5G showed that
overexpressed NF90 could downregulate the
wild-type but not the mutant miR-145 (top panel),
although the levels of overexpressed NF90 were
comparable under different transfection conditions
(bottom panel). These data collectively indicate that a
lncRNA-LET/NF90/miR-145 axis exists in UBC cells.

Figure 5. NF90 regulates miR-145 biogenesis. (A) Cluster map of microarray showed the altered miRNAs ≥ 2 folds in NF90 knockdown cells, compared with
control group (siNC). (B) mRNA level of miR-145 was measured by qRT-PCR in control (siNC) and NF90 knockdown (siNF90) T24 and 5637 cells. (C) qRT-PCR
showing the level of miR-145 in control (siNC) and lncRNA-LET knockdown (siLET-#1 and siLET-#2) T24 cells. (D) The levels of miR-145 and miR-143 in control
(shCTL) and lncRNA-LET stable knockdown (shLET) T24 cells. (E) RIP combined with qRT-PCR assays of NF90 binding to pri-miR-143 or pri-miR-145 in control
(shCTL) or lncRNA-LET knockdown (shLET) T24 cells. Relative enrichment of pri-miRNAs in anti-NF90 group, compared with IgG group. The control GAPDH
mRNA level was used for normalization. (F) Schematic illustration of wild-type (WT) and mutant (Mut) miR-145 with consensus binding motif of NF90. (G) qRT-PCR
analysis of exogenous miR-145 levels in T24 cells, transfected with wild-type or mutant NF90 binding site pri-miR-145 vector. Expression of FLAG in Western blotting
was used to represent the NF90 transfection efficiency. Data are shown as mean ± SD and represent at least two independent experiments with similar results. * P
< 0.05, ** P < 0.01, *** P < 0.001 (Student’s unpaired two-tailed t-test).
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miR-145 suppresses markers of cancer
stemness
To determine if miR-145 plays any role in cancer
stemness, we transfected miR-145 mimic into UBC
cells and monitored its effect on stemness markers.
Fig. S5D shows that miR-145 repressed GEM-induced
ALDHhigh population. Western blotting data further
confirmed the effect of miR-145 on CSC population
evidenced by the cancer stemness markers in T24 cells
(Fig. S5E). Bioinformatic analyses found that both
KLF4 and HMGA2 contain a potential miR-145
binding site in their 3’-UTRs (Fig. S5F). We then
co-transfected T24 cells with miR-145 and reporters
driven by either wild-type or mutant 3’-UTRs of the
KLF4 or the HMGA2 and studied the effects of
miR-145 on reporter activity. Fig. S5G shows that
miR-145 inhibited reporter activities controlled by
wild-type, but not mutant 3’-UTRs of either gene,
suggesting that miR-145 is involved in the
downregulation of these stemness markers.
Consistently, ectopic expression of both KLF4 and
HMGA2 were able to rescue the inhibitory effects of
miR-145 against cancer stemness (Fig. S5H-I).

Inhibition of TGFβ1 signaling pathway
suppressed GEM-induced UBC stemness
Next, we examined whether TGFβ signaling
pathway is involved in GEM-induced cancer
stemness. Using the protocol that UBC cells were
transiently treated with GEM followed by removal of
GEM for cancer cell recovery (Fig. S2A and S2B), we
observed that GEM treatment increased ALDHHigh
subpopulation in T24 cells. However, depletion of
SMAD4 by RNA interfering significantly reversed the
induction of CSC population (Fig. S6A), supported by
consistent changes of CSC markers expression levels
(ALDH1A1 and CD44; Fig. S6B). To further validate
whether lncRNA-LET/NF90/miR-145 axis are
regulated by TGFβ1 pathway in GEM resistant UBC
cells, we performed qRT-PCR and found that GEM
treatment-repressed lncRNA-LET and miR-145 were
significantly increased when SMAD4 was depleted
(Fig. S6C and S6D). Western blotting data also
confirmed that GEM treatment stabilized NF90
protein, which was abrogated once SMAD4 was
knocked down (Fig. S6B). Overall, in vitro data
supported
the
notion
that
alteration
of
lncRNA-LET/NF90/miR-145 axis by TGFβ1 signaling
accounts for GEM-mediated regulation of UBC
stemness.

Inhibition of TGFβ1 signaling pathway
sensitized GEM-resistant xenograft to
chemotherapy
Given that activation of TGFβ1 signaling
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pathway in recurrent UBC xenografts under GEM
treatment, which is essential for cancer cell stemness,
we hypothesize that targeting TGFβ1 pathway may
reduce CSC population and enhance efficacy of
chemotherapy. To examine this hypothesis, we s.c.
injected chemoresistant T24 cells, which were
primarily cultured from recurrent xenografts under
GEM treatment. Once we followed previous regimen,
GEM showed slight anticancer effects; while
LY2157299, a specific inhibitor to type I TGFβ receptor
kinase, did not show remarkable reduction. Notably,
combined treatment with LY21577299 and GEM
significantly and strikingly repressed tumorigenicity
in vivo (Fig. 6A and B). By primarily culturing cancer
cells from four different T24 xenograft groups, we
found that, compared to untreatment group,
suppressing TGFβ1 pathway significantly reduced
CSC population, though GEM alone did not further
enrich CSC subpopulation in GEM-resistant T24 cells
derived from previous GEM treatment (Fig. 6C).
Western blotting data confirmed the successful
inhibition of TGFβ1 pathway (Fig. 6D). Taken
together, targeting TGFβ1 pathway may be a
promising
approach
to
suppress
GEM
treatment-induced cancer stemness and sensitize UBC
cells to chemotherapy.

Clinical relevance of
lncRNA-LET/NF90/miR-145 axis in UBC
specimens
To determine the significance of the
TGFβ1/lncRNA-LET/NF90/miR-145 regulatory axis
in clinical UBC specimens, we analyzed their
expression levels in 60 UBC samples and 48 adjacent
normal tissues. Compared with those in the normal
tissues, the levels of NF90 and TGFβ1 in these human
UBC samples were significantly increased about 5.0
(Fig. 7A-B) and 1.5 folds (Fig. 7B), respectively. On the
other hand, the levels of lncRNA-LET and miR-145 in
tumors were significantly reduced by about 52% and
92%, respectively (Fig. 7A). The expression level of
lncRNA-LET is significantly associated with tumor
stage, microvascular invasion, lymph node metastasis
and recurrence (Table S3). More importantly, the level
of lncRNA-LET in tumor tissues was negatively
correlated with TGFβ1 (r = -0.6083; P < 0.0001) and
NF90 (r = -0.4814; P = 0.0017), but positively
correlated with miR-145 (r = 0.4967; P < 0.0001; Fig.
7C). To examine the prognostic significance of TGFβ1,
lncRNA-LET, and miR-145 expression levels, we
performed Kaplan-Meier survival analysis of UBC
patients. UBC patients which displayed lower
expression levels of lncRNA-LET and miR-145 had a
reduced survival rate, whereas TGFβ1 expression
level did not show significant difference in clinical
http://www.thno.org
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outcome. Moreover, UBC patients with a profile of
TGFβ1low/lncRNA-LEThigh/miR-145high showed a
better survival rate compared with patients with other
expression
profiles,
such
as
TGFβhigh
low
low
/lncRNA-LET /miR-145 (Fig. 7D). Overall, these
data suggest that TGFβ1high/lncRNA-LETlow/
miR-145low signature could be served as a predictor of
clinical outcome in UBC patients.

Discussion
Tumor chemoresistance and subsequent relapse
are common in cancers, which raises a key issue for
clinicians. Accumulating evidence supports the
notion that a small population of CSCs inside the
heterogeneous tumor bulk could be accountable for
tumor recurrence (8, 28). The CSCs have intrinsic
chemoresistant properties and can be selectively
enriched during chemotherapy. In this study, we
found that UBC stemness is enhanced during
chemotherapy with GEM in vivo, evidenced by the
increased levels of CSC markers, such as CK14, CK5
and CD44. This is consistent with the observation that
cytotoxic chemotherapy induced CK14+ cancer cell
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proliferation despite reducing tumor size at initial
chemotherapy cycle (29). Based on the data from both
in vitro and in vivo experiments, we propose that
TGFβ1 is upregulated by GEM treatment, and the
TGFβ1-mediated
dysregulation
of
the
lncRNA-LET/NF90/miR-145 axis promotes cancer
cell stemness in residual tumors and subsequently
results in chemoresistance (Fig. 7E).
LncRNAs have been found to be frequently
dysregulated in cancers and implicated in cancer
stemness and chemoresistance (30, 31). LncRNA-LET
has been reported to be underexpressed in cancers of
digestive system and associated with cancer
metastasis (25, 32, 33). We found that lncRNA-LET
was also down-regulated in chemoresistant human
UBC xenografts. The downregulation of lncRNA-LET
was accompanied by increased NF90 protein stability,
reduced biogenesis of miR-145, as well as elevated
levels of stemness markers. These data indicate that
lncRNA-LET plays a central role in the regulation of
UBC stemness because forced expression of
lncRNA-LET reduces UBC stemness markers and
delays tumor relapse.

Figure 6. Inhibition of TGFβ1 signaling pathway enhances chemosensitivity to GEM treatment in T24 UBC xenografts. (A) Tumor size change of
xenografts from chemoresistant T24 cells treated with vehicle, LY2157299, GEM or both LY2157299 and GEM (n=6 per group). (B) Tumor volumes calculated on
day 30 (n=6 per group). (C) ALDEFLUOR assay. The primary cells derived from xenografts were harvested on day 30, and analyzed for ALDH activity. (D) Western
blotting of pSMAD2 and total SMAD2 in xenografts of the four groups. Data are shown as mean ± SD. ** P < 0.01 (Student’s unpaired two-tailed t-test).
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Figure 7. Clinical relevance of lncRNA-LET/NF90/miR-145 axis in UBC specimens. (A). The levels of lncRNA-LET, TGFβ1, miR-145, and that of NF90 in
human UBC (Tumor) and the adjacent normal tissues (Normal). Mann Whitney test, Unpaired t test or Wilcoxon signed rank test was used for analysis of statistical
significance. (B) Western blotting showing NF90 expression in paired UBC (T) and adjacent normal tissues (N). (C) The correlations among lncRNA-LET, TGFβ1,
miR-145 and NF90 were determined by Pearson correlation analysis. ΔCT values of qRT-PCR were used as the levels of lncRNA-LET, TGFβ1 and miR-145
transcripts. NF90 protein bands on Western blotting were semi-quantified by Image J. (D) Kaplan-Meier survival analysis of overall survival of 60 UBC patients with
expression profile of TGFβ1high vs TGFβ1low, lncRNA-LET high vs lncRNA-LETlow, miR-145 high vs miR-145low. Subgroup analysis of UBC patients according to the
expression profile of TGFβ1high/lncRNA-LETlow/miR-145low signature versus the other combinations. Median value was chosen as cut-off point. The log-rank
(Mantel-Cox) test was used to calculate P-values. P < 0.05 was considered statistically significant. (E) Schematic illustration of enhancement of cancer stem-like cell
properties in GEM resistant UBC cells by the dysregulation of lncRNA-LET/NF90/miR-145 axis via TGFβ1.

Maintenance of cancer stemness can also be
regulated by extracellular cue. We found that in
GEM-treated UBC xenografts TGFβ1 was upregulated
and functional. This is consistent with the recent
report showing that TGFβ signaling was strongly
activated after paclitaxel treatment in triple-negative
breast cancer tissues (34). The induction of TGFβ1
could be the results of autocrine or paracrine. We
have reported that cancer-associated fibroblasts in
tumor microenvironment is capable of enhancing the

expression of TGFβ1 than cancer cells (35). In
addition, TGFβ1 could also be derived from other cell
types, including immune cells which are often
recruited to tumor region during therapy (36, 37).
Nevertheless, down-regulation of lncRNA-LET by
overactivation of TGFβ/SMAD signaling pathway in
UBC cells suggests cytokines such as TGFβ1 play
important role in the regulation of UBC stemness.
We demonstrated that in different UBC cell lines
lncRNA-LET could increase NF90 degradation
http://www.thno.org
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through the ubiquitin-proteasome pathway, similar to
that in hepatoma cell lines (25). NF90 is a
double-stranded RNA binding protein involved in
stabilization, turnover and translational control of
different target mRNAs, including interleukin 2
(IL-2), hypoxia-inducible factor 1 alpha (HIF-1α) and
vascular endothelial growth factor (VEGF) (25, 38-40).
We found that VEGF, but not HIF-1α, was elevated in
UBC cells with knockdown of lncRNA-LET. This
suggests that in UBC cells the lncRNA-LET/NF90 axis
regulating VEGF and HIF1 differently. In addition to
regulating the expression of different genes
post-transcriptionally, NF90 also takes part in miRNA
biogenesis. As a competitor for the association of the
microprocessor complex with pri-miRNAs, NF90
usually inhibits miRNA production (27, 41, 42). We
found that lncRNA-LET depletion resulted in
elevated level of NF90 which in turn blocks miR-145
biogenesis by competitively binding to pri-miR-145
specifically. Of note, both miR-143 and miR-145 locate
on chromosome 5q33 with approximately 1.3 kb away
from each other. An 11 kb transcript serves as the
precursor of both miRNAs, albeit miR-145 can be
generated from another 1.9 kb transcript precursor
(43). It has been proposed previously that during
bladder CSCs enrichment the expression of miR-145
could be regulated by an undefined mechanism (44,
45). Here we demonstrated that miR-145 biogenesis
can be regulated by lncRNA-LET/NF90 axis.
Although it is known that miR-145 negatively
regulates human embryonic stem cells and CSCs, it is
unclear whether it regulates the stemness markers
indirectly or directly (45-48). We demonstrated in this
report that in UBC cells KLF4 and HMGA2, two
miR-145 targets, are responsible for miR-145 mediated
inhibition of UBC cell stemness.
In the current study, we also examined whether
TGFβ signaling pathway could be a promising
therapeutic target to enhance chemosensitivity of
UBC cells to GEM in vivo. LY2157299, also known as
galunisertib, is a selective ATP-mimetic inhibitor of
TGF-βRI serine/threonine kinase. It displayed
antitumor activity, as well as acceptable tolerability
and safety profile in cancer patients with advanced
tumors, such as glioma (49-51). In the in vivo study
herein, combined treatment of LY2157299 with GEM
significantly reduced CSC subpopulation and
tumorigenecity compared with either drug alone. This
intriguing data support the notion that overactivation
of TGFβ signaling pathway during tumor relapse can
serve as a promising therapeutic target for UBC
patients under chemotherapy.
In conclusion, our data demonstrated that GEM,
which is commonly used for the treatment fo UBC
patients, can induce TGFβ1 in recurrent tumors. The
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elevated TGFβ1 induces a regulatory axis of
lncRNA-LET/NF90/miR-145 in UBC cells to increase
CSC populations and promote chemoresistance. The
notion that TGFβ1high/lncRNA-LETlow/miR-145low
signature in clinical samples were correlated with
poor prognosis reinforces the importance of this
regulatory axis for UBC patients. Interestingly, forced
expression of lncRNA-LET maintained the sensitivity
of UBC cells to GEM and delaying tumor relapse,
suggesting that either targeting TGFβ signaling
pathway, restoration of lncRNA-LET expression or
reintroduction of its downstream target miRNA could
be an attractive anti-tumor approach for integrated
cancer therapy (49, 52, 53).

Statement of translational relevance
Gemcitabine is commonly used in combinatory
chemotherapy for muscle invasive bladder cancer
patients in the neoadjuvant, adjuvant and palliative
setting. However, the duration of response in various
combinations and survival results is limited in the
advanced or metastatic bladder cancers. Hence, it is
needed for biomarkers of prognosis and drug
response, as well as potential drug targets. To address
this question, we identified that lncRNA-LET is
downregulated in gemcitabine resistant bladder
cancers, which is directly and negatively regulated
pro-inflammatory cytokine TGFβ1. Importantly, the
forced expression of lncRNA-LET delays bladder
cancer recurrence under gemcitabine treatment. We
also identified that lncRNA-LET/NF90/miR-145 axis
in recurrent bladder cancer samples will provide
better understanding of maintenance of cancer cell
stemness. Moreover, the combined changes in
TGFβ1/lncRNA-LET/miR-145
provide
novel
molecular prognostic markers in bladder cancer
outcome. Abrogation of TGFβ1 pathway by
LY2157299 sensitized bladder cancer cells to
gemcitabine in vivo.
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